MCID: PYR010
MIFTS: 53

Peyronie's Disease

Categories: Reproductive diseases, Rare diseases

Aliases & Classifications for Peyronie's Disease

MalaCards integrated aliases for Peyronie's Disease:

Name: Peyronie's Disease 41 12 15
Peyronie Disease 12 73
Balanitis Xerotica Obliterans 73
Induratio Penis Plastica 12
Peyronie's Fibromatosis 12
Peyronies Disease 41
Penile Induration 44

Classifications:



External Ids:

Disease Ontology 12 DOID:8616
ICD10 33 N48.6
ICD9CM 35 607.85
MeSH 44 D010411
NCIt 50 C3316
UMLS 73 C0030848

Summaries for Peyronie's Disease

MalaCards based summary : Peyronie's Disease, also known as peyronie disease, is related to peyronie disease and dupuytren contracture. An important gene associated with Peyronie's Disease is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Acetylcholine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include small intestine, bone and prostate, and related phenotypes are cellular and craniofacial

Wikipedia : 76 Peyronie\'s disease is a connective tissue disorder involving the growth of fibrous plaques in the soft... more...

Related Diseases for Peyronie's Disease

Diseases in the Peyronie Disease family:

Peyronie's Disease

Diseases related to Peyronie's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
# Related Disease Score Top Affiliating Genes
1 peyronie disease 33.9 IFNA2 TGFB1 TGFB2
2 dupuytren contracture 31.7 DCN TGFB1
3 ledderhose disease 10.9
4 cutaneous polyarteritis nodosa 10.5 IFNA2 SMAD3
5 giant hemangioma 10.5 IFNA2 TGFB1
6 stiff skin syndrome 10.4 TGFB1 TGFB2
7 loeys-dietz syndrome 4 10.4 TGFB2 TGFB3
8 multilocular clear cell renal cell carcinoma 10.4 TGFB2 TGFB3
9 adenosquamous pancreas carcinoma 10.2 IFNA2 SMAD4
10 hypertrophic scars 10.2 SMAD3 TGFB1 TGFB3
11 polyarteritis nodosa 10.1 IFNA2 SMAD3
12 tuberculoid leprosy 10.1 TGFB1 TGFB2 TGFB3
13 impotence 10.0
14 tuberculous meningitis 10.0 CCL2 TGFB1
15 macular holes 10.0 CCL2 TGFB2
16 loeys-dietz syndrome 10.0 SMAD3 TGFB2 TGFB3
17 pustulosis palmaris et plantaris 10.0 SMAD7 TGFB1
18 localized scleroderma 10.0 DCN SMAD3 TGFB1
19 urinary tract obstruction 10.0 CCL2 SMAD3 TGFB1
20 vitreoretinopathy, neovascular inflammatory 9.9 CCL2 TGFB1 TGFB2
21 pulmonary fibrosis, idiopathic 9.8 CCL2 SMAD3 TGFB1
22 uveitis 9.8 CCL2 IFNA2 TGFB2
23 hypochondrogenesis 9.8 SMAD3 SMAD7 TGFB3
24 mucositis 9.7
25 tendinosis 9.7 DCN TGFB2
26 penile disease 9.6 DCN IFNA2 SMAD3 TGFB1
27 nephrosclerosis 9.6 CCL2 TGFB1
28 colitis 9.6 SMAD3 SMAD4 SMAD7
29 keloids 9.5 SMAD3 SMAD7 TGFB1 TGFB3
30 ureteral disease 9.3 CCL2 SMAD3 SMAD7 TGFB1
31 renal fibrosis 9.3 CCL2 SMAD3 SMAD7 TGFB1
32 pulmonary fibrosis 9.2 CCL2 SMAD3 SMAD7 TGFB1
33 inflammatory bowel disease 9.1 CCL2 SMAD3 SMAD7 TGFB1
34 nephrogenic systemic fibrosis 8.7 DCN SMAD3 SMAD4 SMAD7 TGFB1

Comorbidity relations with Peyronie's Disease via Phenotypic Disease Network (PDN):


Bladder Neck Obstruction Prostatic Hypertrophy
Urethral Stricture

Graphical network of the top 20 diseases related to Peyronie's Disease:



Diseases related to Peyronie's Disease

Symptoms & Phenotypes for Peyronie's Disease

MGI Mouse Phenotypes related to Peyronie's Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 TGFB2 TGFB3 SMAD7 DCN TGFB1 SMAD3
2 craniofacial MP:0005382 10 TGFB3 TGFB1 SMAD3 TGFB2 SMAD4 DCN
3 digestive/alimentary MP:0005381 9.98 TGFB3 TGFB1 SMAD3 TGFB2 SMAD4 DCN
4 embryo MP:0005380 9.88 TGFB3 TGFB1 SMAD3 TGFB2 SMAD4 SMAD7
5 hematopoietic system MP:0005397 9.87 TGFB3 TGFB1 SMAD3 TGFB2 SMAD4 DCN
6 immune system MP:0005387 9.86 TGFB3 TGFB1 SMAD3 TGFB2 SMAD4 CCL2
7 endocrine/exocrine gland MP:0005379 9.85 TGFB2 DCN TGFB1 SMAD3 SMAD4 SMAD7
8 renal/urinary system MP:0005367 9.55 TGFB1 SMAD3 TGFB2 SMAD4 DCN
9 reproductive system MP:0005389 9.43 TGFB1 SMAD3 TGFB2 SMAD4 DCN SMAD7
10 skeleton MP:0005390 9.1 TGFB3 TGFB1 SMAD3 TGFB2 SMAD4 DCN

Drugs & Therapeutics for Peyronie's Disease

Drugs for Peyronie's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 2 51-84-3 187
2
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
3 abobotulinumtoxinA Phase 2
4 Botulinum Toxins Phase 2
5 Botulinum Toxins, Type A Phase 2
6 Cholinergic Agents Phase 2
7 Neuromuscular Agents Phase 2
8 Neurotransmitter Agents Phase 2
9 onabotulinumtoxinA Phase 2
10 Peripheral Nervous System Agents Phase 2
11 Pharmaceutical Solutions Phase 2
12 Anesthetics Phase 2
13 Anesthetics, Local Phase 2
14 Anti-Arrhythmia Agents Phase 2
15 Central Nervous System Depressants Phase 2
16 Diuretics, Potassium Sparing Phase 2
17 Sodium Channel Blockers Phase 2
18
Methyltestosterone Approved Phase 1 58-18-4 6010
19
Testosterone Approved, Investigational Phase 1 58-22-0 6013
20
Testosterone enanthate Approved Phase 1 315-37-7 9416
21
Testosterone undecanoate Approved, Investigational Phase 1 5949-44-0
22
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
23
Tocopherol Approved, Investigational, Nutraceutical Phase 1 1406-66-2 14986
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
25
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
26 Anabolic Agents Phase 1
27 Androgens Phase 1
28 Antineoplastic Agents, Hormonal Phase 1
29 Antioxidants Phase 1
30 Bone Density Conservation Agents Phase 1
31 Ergocalciferols Phase 1
32 Hormone Antagonists Phase 1
33 Hormones Phase 1
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1
35 Micronutrients Phase 1
36 Protective Agents Phase 1
37 Testosterone 17 beta-cypionate Phase 1
38 Tocopherols Phase 1
39 Tocotrienols Phase 1
40 Trace Elements Phase 1
41 Vitamins Phase 1
42 Calciferol Nutraceutical Phase 1
43 Tocotrienol Investigational, Nutraceutical Phase 1 6829-55-6
44 Vitamin D2 Nutraceutical Phase 1
45 Phosphodiesterase 5 Inhibitors

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
2 A Study of AA4500 in Men With Peyronie's Disease Completed NCT01243411 Phase 3
3 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221597 Phase 3
4 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221623 Phase 3
5 An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease Completed NCT02267460 Phase 3
6 Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) Unknown status NCT01184586 Phase 2
7 The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
8 Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Completed NCT01430169 Phase 2
9 H-22411: BOTOX® for Peyronie's Disease Recruiting NCT00812838 Phase 2 100 units of Botulinum Toxin Type A
10 Intracavernosal Injection of Botulinum Toxin Type A (50 and 100 Unit) in the Treatment of Erectile Dysfunction Enrolling by invitation NCT03355963 Phase 2
11 Clostridium Histolyticum Collagenase Injection for Urethral Disease Not yet recruiting NCT02948842 Phase 2 Clostridium Histolyticum Collagenase;Lidocaine
12 Peyronie's Disease Treatment Protocol Completed NCT02072018 Phase 1 H-100;Placebo
13 Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Completed NCT01578473 Phase 1 Vitamin D2;Vitamin E;Testosterone Pellets
14 Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD Completed NCT02395029 Phase 1
15 Management of Peyronie's Disease With Adipose Tissue Stem Cell Unknown status NCT02414308 Not Applicable Adipose tissue stem cell injection
16 Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830 Not Applicable
17 Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease Completed NCT02298829 Subjects Previously Treated with AA4500
18 Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy Completed NCT00800813
19 Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease. Recruiting NCT03530540 Not Applicable
20 Efficacy of Penile Traction Therapy Using a Novel Device Recruiting NCT03389854 Not Applicable
21 Penile Length Maintenance Post-Prostatectomy Recruiting NCT03500419 Not Applicable
22 Outcomes of Surgical Correction of Penile Curvature in Adult Not yet recruiting NCT03313986

Search NIH Clinical Center for Peyronie's Disease

Cochrane evidence based reviews: penile induration

Genetic Tests for Peyronie's Disease

Anatomical Context for Peyronie's Disease

MalaCards organs/tissues related to Peyronie's Disease:

41
Small Intestine, Bone, Prostate, Endothelial, Monocytes, Testes, Eye

Publications for Peyronie's Disease

Articles related to Peyronie's Disease:

(show top 50) (show all 699)
# Title Authors Year
1
Patient's choice of health information and treatment modality for Peyronie's disease: a long-term assessment. ( 29795531 )
2018
2
Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study. ( 29733116 )
2018
3
2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature. ( 29792593 )
2018
4
Contemporary Review of Peyronie's Disease Treatment. ( 29774446 )
2018
5
Surgical correction of Peyronie's disease via tunica albuginea plication: long-term follow-up. ( 29195031 )
2018
6
Grafts for Peyronie's disease: a comprehensive review. ( 29266877 )
2018
7
Prospective study to evaluate the clinical outcome of intralesional interferon-I+2b in the management of Peyronie's disease. ( 29719326 )
2018
8
Five Things I Wish I Would Have Known Earlier in My Career: Lessons Learned in Peyronie's Disease Surgery. ( 29861359 )
2018
9
Patient's choice of health information and treatment modality for Peyronie's disease: a long term assessment. ( 29880823 )
2018
10
Characterization of Septal and Punctate Scarring in Peyronie's Disease. ( 29800632 )
2018
11
Plaque calcification: An important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie's Disease. ( 29908867 )
2018
12
A Comparative Study Between 2 Different Grafts Used as Patches After Plaque Incision and Inflatable Penile Prosthesis Implantation for End-Stage Peyronie's Disease. ( 29753801 )
2018
13
Surgical Outcomes of Plaque Excision and Grafting and Supplemental Tunica Albuginea Plication for Treatment of Peyronie's Disease With Severe Compound Curvature. ( 29802005 )
2018
14
The relationship between penile deformity, age, psychological bother, and erectile dysfunction in a sample of men with Peyronie's Disease (PD). ( 29795530 )
2018
15
Reduction in Peyronie's-like plaque size using a vacuum erection device in a rat model of Peyronie's disease via the TGF-I^/SMAD signalling pathway. ( 29806152 )
2018
16
Peyronie's disease and Dupuytren's contracture secondary to topical timolol. ( 29423783 )
2018
17
Understanding the Role of Adenosine Receptors in the Myofibroblast Transformation in Peyronie's Disease. ( 29891411 )
2018
18
Collagenase clostridium histolyticum: a novel medical treatment for Peyronie's disease. ( 29761688 )
2018
19
Malleable Penile Implant Is an Effective Therapeutic Option in Men With Peyronie's Disease and Erectile Dysfunction. ( 29336942 )
2018
20
Editorial Comment on "Penile Prosthesis Implantation in Patients With Peyronie's Disease: Results of the PROPPER Study Demonstrate a Decrease In Patient-Reported Depression". ( 29803353 )
2018
21
The PICS Technique: A Novel Approach for Residual Curvature Correction During Penile Prosthesis Implantation in Patients With Severe Peyronie's Disease Using the Collagen Fleece TachoSil. ( 29325832 )
2018
22
Re: Extracorporeal Shock Wave Therapy (ESWT) in Urology: A Systematic Review of Outcome in Peyronie's Disease, Erectile Dysfunction, and Chronic Pelvic Pain. ( 29449032 )
2018
23
Predictors of treatment success after collagenase Clostridium histolyticum injection for Peyronie's disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study. ( 29791971 )
2018
24
Increased Risk of Incident Disease in Men with Peyronie's Disease: Analysis of U.S. Claims Data. ( 29803352 )
2018
25
Clinical Factors Negatively Impacting Sexual Relationships in Men With Peyronie's Disease. ( 29144850 )
2017
26
Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. ( 28612401 )
2017
27
Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application. ( 28791261 )
2017
28
Treatment of Peyronie's disease via preoperative intralesional collagenase clostridium histolyticum followed by placement of an inflatable penile prosthesis: the new standard of care? ( 29239395 )
2017
29
Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option. ( 28879693 )
2017
30
Role of interleukin-6 and pentraxin 3 as an early marker in Peyronie's disease. ( 28359407 )
2017
31
The combination of penile revascularization surgery with penile corrective techniques as an alternative to prosthesis implantation in patients with peyronie's disease accompanied by erectile dysfunction: Long-term results. ( 29255189 )
2017
32
Successful Treatment of Residual Curvature in Peyronie's Disease in Men Previously Treated with Intralesional Collagenase Clostridium Histolyticum. ( 28886994 )
2017
33
Sonographic patterns of Peyronie's disease in patients with absence of palpable plaques. ( 29211402 )
2017
34
Recent Pathophysiological Aspects of Peyronie's Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review. ( 28744308 )
2017
35
Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study. ( 28718527 )
2017
36
Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease. ( 28554517 )
2017
37
Collagenase clostridium hystolyticum in the management of Peyronie's disease. ( 28540240 )
2017
38
Sexual dysfunction: Shortened CCH treatment for Peyronie's disease. ( 28675171 )
2017
39
Re: Bicentric Prospective Evaluation of Corporoplasty with Porcine Small Intestinal Submucosa (SIS) in Patients with Severe Peyronie's Disease. ( 29144916 )
2017
40
Effect of Penile Traction and Vacuum Erectile Device for Peyronie's Disease in an Animal Model. ( 28923308 )
2017
41
Response and Rebuttal to Letter to the Editor: Evidence-Based Management Guidelines on Peyronie's Disease. ( 28065353 )
2017
42
Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol. ( 28874327 )
2017
43
Repeated Micro-Trauma of the Penile Tunica Albuginea: A New Animal Model of Peyronie's Disease. ( 29151107 )
2017
44
Penile prosthetic surgery for the management of Peyronie's disease. ( 29238661 )
2017
45
Shame, Catastrophizing, and Negative Partner Responses Are Associated With Lower Sexual and Relationship Satisfaction and More Negative Affect in Men With Peyronie's Disease. ( 26836296 )
2017
46
Commentary on "Nondegloving technique for Peyronie's disease with penile prosthesis implantation and double dorsal-ventral patch graft". ( 29205179 )
2017
47
Surgical outcomes from limiting the use of nonabsorbable suture in tunica albuginea plication for Peyronie's disease. ( 28835714 )
2017
48
Extracellular matrix alterations in the Peyronie's disease. ( 28721300 )
2017
49
Conservatively Managed Peyronie's Disease-Long-term Survey Results From Patients Undergoing Nonsurgical and Noninjection Therapies. ( 29174623 )
2017
50
Re: Factors Associated with Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients with Peyronie Disease. ( 29144914 )
2017

Variations for Peyronie's Disease

Expression for Peyronie's Disease

Search GEO for disease gene expression data for Peyronie's Disease.

Pathways for Peyronie's Disease

Pathways related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 ACTG2 CCL2 SMAD3 SMAD4 TGFB1 TGFB2
2
Show member pathways
13.59 ACTG2 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
3
Show member pathways
13.59 CCL2 IFNA2 SMAD3 SMAD4 TGFB1 TGFB2
4
Show member pathways
13.44 CCL2 IFNA2 SMAD3 SMAD4 TGFB1 TGFB2
5
Show member pathways
13.28 ACTG2 CCL2 TGFB1 TGFB2 TGFB3
6
Show member pathways
13.28 ACTG2 CCL2 TGFB1 TGFB2 TGFB3
7
Show member pathways
13.25 ACTG2 CCL2 SMAD3 SMAD4 TGFB1 TGFB2
8
Show member pathways
12.98 CCL2 IFNA2 SMAD3 TGFB1 TGFB2 TGFB3
9
Show member pathways
12.83 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
10
Show member pathways
12.82 ACTG2 TGFB1 TGFB2 TGFB3
11 12.8 IFNA2 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
12
Show member pathways
12.77 ACTG2 TGFB1 TGFB2 TGFB3
13
Show member pathways
12.74 SMAD3 SMAD4 SMAD7 TGFB1
14
Show member pathways
12.73 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
15
Show member pathways
12.67 DCN TGFB1 TGFB2 TGFB3
16
Show member pathways
12.53 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
17
Show member pathways
12.49 IFNA2 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
18
Show member pathways
12.47 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
19
Show member pathways
12.44 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
20 12.42 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
21 12.36 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
22
Show member pathways
12.28 SMAD3 SMAD4 SMAD7 TGFB1
23
Show member pathways
12.26 TGFB1 TGFB2 TGFB3
24
Show member pathways
12.26 SMAD3 SMAD4 SMAD7
25
Show member pathways
12.24 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
26 12.23 IFNA2 TGFB1 TGFB2 TGFB3
27 12.21 DCN TGFB1 TGFB2
28
Show member pathways
12.21 SMAD3 SMAD4 TGFB1 TGFB2
29 12.21 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
30
Show member pathways
12.17 TGFB1 TGFB2 TGFB3
31 12.17 SMAD3 TGFB1 TGFB2 TGFB3
32
Show member pathways
12.14 TGFB1 TGFB2 TGFB3
33 12.14 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
34 12.08 SMAD3 SMAD4 SMAD7 TGFB1
35
Show member pathways
12.05 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
36 12.03 SMAD3 SMAD4 SMAD7 TGFB1 TGFB2 TGFB3
37 11.99 ACTG2 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
38
Show member pathways
11.96 CCL2 SMAD3 SMAD4 SMAD7 TGFB1 TGFB2
39 11.95 SMAD3 SMAD4 TGFB1
40 11.91 SMAD3 SMAD4 TGFB1
41 11.88 CCL2 TGFB1 TGFB2 TGFB3
42 11.87 CCL2 TGFB1 TGFB2 TGFB3
43 11.86 TGFB1 TGFB2 TGFB3
44
Show member pathways
11.85 SMAD3 SMAD4 TGFB1
45
Show member pathways
11.76 SMAD3 SMAD4 TGFB1
46 11.76 SMAD3 SMAD4 SMAD7
47 11.75 SMAD3 SMAD4 SMAD7 TGFB1
48
Show member pathways
11.73 TGFB1 TGFB2 TGFB3
49
Show member pathways
11.73 SMAD3 SMAD4 SMAD7 TGFB1
50 11.73 CCL2 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3

GO Terms for Peyronie's Disease

Cellular components related to Peyronie's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 CCL2 DCN IFNA2 TGFB1 TGFB2 TGFB3
2 transcription factor complex GO:0005667 9.5 SMAD3 SMAD4 SMAD7
3 platelet alpha granule lumen GO:0031093 9.33 TGFB1 TGFB2 TGFB3
4 SMAD protein complex GO:0071141 9.26 SMAD3 SMAD4
5 extracellular matrix GO:0031012 9.26 DCN TGFB1 TGFB2 TGFB3
6 extracellular space GO:0005615 9.17 ACTG2 CCL2 DCN IFNA2 TGFB1 TGFB2

Biological processes related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.92 IFNA2 TGFB1 TGFB2
2 response to hypoxia GO:0001666 9.91 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
3 in utero embryonic development GO:0001701 9.9 SMAD3 SMAD4 TGFB3
4 aging GO:0007568 9.9 DCN TGFB1 TGFB3
5 negative regulation of cell growth GO:0030308 9.9 SMAD3 SMAD4 TGFB1 TGFB2
6 cell cycle arrest GO:0007050 9.89 SMAD3 TGFB1 TGFB2
7 platelet degranulation GO:0002576 9.89 TGFB1 TGFB2 TGFB3
8 kidney development GO:0001822 9.88 DCN SMAD4 TGFB2
9 roof of mouth development GO:0060021 9.88 SMAD4 TGFB2 TGFB3
10 cell development GO:0048468 9.87 TGFB1 TGFB2 TGFB3
11 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.87 SMAD3 SMAD7 TGFB1 TGFB3
12 cellular response to transforming growth factor beta stimulus GO:0071560 9.86 SMAD3 SMAD7 TGFB1
13 regulation of MAPK cascade GO:0043408 9.86 TGFB1 TGFB2 TGFB3
14 inner ear development GO:0048839 9.85 TGFB1 TGFB2 TGFB3
15 positive regulation of cell division GO:0051781 9.84 TGFB1 TGFB2 TGFB3
16 extrinsic apoptotic signaling pathway GO:0097191 9.84 SMAD3 TGFB1 TGFB2
17 response to progesterone GO:0032570 9.83 TGFB1 TGFB2 TGFB3
18 ureteric bud development GO:0001657 9.83 SMAD3 SMAD7 TGFB1
19 positive regulation of protein secretion GO:0050714 9.83 TGFB1 TGFB2 TGFB3
20 positive regulation of bone mineralization GO:0030501 9.81 SMAD3 TGFB1 TGFB3
21 ventricular septum morphogenesis GO:0060412 9.81 SMAD4 SMAD7 TGFB2
22 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.8 SMAD4 TGFB1 TGFB2 TGFB3
23 BMP signaling pathway GO:0030509 9.8 SMAD4 SMAD7 TGFB1 TGFB2 TGFB3
24 endoderm development GO:0007492 9.79 SMAD3 SMAD4 TGFB1
25 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.78 SMAD3 TGFB1 TGFB2
26 cell growth GO:0016049 9.77 TGFB1 TGFB2 TGFB3
27 wound healing GO:0042060 9.77 DCN SMAD3 TGFB1 TGFB2 TGFB3
28 pathway-restricted SMAD protein phosphorylation GO:0060389 9.76 SMAD7 TGFB1 TGFB2
29 digestive tract development GO:0048565 9.75 TGFB1 TGFB3
30 secondary palate development GO:0062009 9.75 SMAD4 TGFB2 TGFB3
31 epithelial to mesenchymal transition GO:0001837 9.74 TGFB1 TGFB2
32 gastrulation GO:0007369 9.74 SMAD3 SMAD4
33 odontogenesis GO:0042476 9.74 TGFB2 TGFB3
34 negative regulation of mitotic cell cycle GO:0045930 9.74 SMAD3 TGFB1
35 mammary gland development GO:0030879 9.74 TGFB1 TGFB3
36 lipopolysaccharide-mediated signaling pathway GO:0031663 9.74 CCL2 TGFB1
37 face morphogenesis GO:0060325 9.73 TGFB1 TGFB3
38 negative regulation of immune response GO:0050777 9.73 TGFB1 TGFB2
39 positive regulation of protein import into nucleus GO:0042307 9.73 SMAD3 TGFB1
40 developmental growth GO:0048589 9.73 SMAD3 SMAD4
41 outflow tract septum morphogenesis GO:0003148 9.73 SMAD4 TGFB2
42 positive regulation of SMAD protein signal transduction GO:0060391 9.73 SMAD4 TGFB1 TGFB3
43 positive regulation of collagen biosynthetic process GO:0032967 9.72 TGFB1 TGFB3
44 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.72 SMAD7 TGFB1
45 negative regulation of DNA replication GO:0008156 9.72 TGFB1 TGFB3
46 salivary gland morphogenesis GO:0007435 9.72 TGFB1 TGFB2 TGFB3
47 uterus development GO:0060065 9.71 SMAD4 TGFB2
48 lens fiber cell differentiation GO:0070306 9.71 SMAD3 TGFB1
49 SMAD protein complex assembly GO:0007183 9.71 SMAD3 SMAD4 TGFB1
50 heart valve morphogenesis GO:0003179 9.7 TGFB1 TGFB2

Molecular functions related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.83 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
2 cytokine activity GO:0005125 9.77 CCL2 IFNA2 TGFB1 TGFB2 TGFB3
3 transcription regulatory region DNA binding GO:0044212 9.71 SMAD3 SMAD4 SMAD7
4 growth factor activity GO:0008083 9.65 TGFB1 TGFB2 TGFB3
5 BMP receptor binding GO:0070700 9.58 TGFB1 TGFB2 TGFB3
6 collagen binding GO:0005518 9.56 DCN SMAD3 SMAD4 SMAD7
7 proximal promoter sequence-specific DNA binding GO:0000987 9.52 SMAD3 SMAD4
8 transcription factor activity, transcription factor binding GO:0000989 9.51 SMAD3 SMAD4
9 type I transforming growth factor beta receptor binding GO:0034713 9.5 SMAD7 TGFB1 TGFB3
10 R-SMAD binding GO:0070412 9.49 SMAD3 SMAD4
11 I-SMAD binding GO:0070411 9.46 SMAD4 SMAD7
12 type II transforming growth factor beta receptor binding GO:0005114 9.33 TGFB1 TGFB2 TGFB3
13 transforming growth factor beta receptor binding GO:0005160 9.26 SMAD3 TGFB1 TGFB2 TGFB3
14 type III transforming growth factor beta receptor binding GO:0034714 8.8 TGFB1 TGFB2 TGFB3

Sources for Peyronie's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....